Entrada Therapeutics, Inc.
TRDA Nasdaq
SEC CIK 1689375
Follow Entrada Therapeutics
Weekly email: filings, results
Revenue, last quarter
$905K
−43.9% vs same quarter last year
Net income
−$39.7M
+10% vs same quarter last year
EPS, diluted
−$0.94
+11.3% vs same quarter last year
Operating cash flow
−$30M
−5.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $25.4M | −$143.8M |
| FY24 | $210.8M | $65.6M |
| FY23 | $129M | −$6.7M |
| FY22 | - | −$94.6M |
| FY21 | - | −$51.2M |
| FY20 | - | −$26.5M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −621.1% | −565.5% |
| FY24 | 22.3% | 31.1% |
| FY23 | −2.5% | −5.2% |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$129.6M |
| FY24 | −$44.7M |
| FY23 | $134.2M |
| FY22 | −$96.7M |
| FY21 | −$55.4M |
| FY20 | −$27.9M |
| FY19 | - |
- Entrada Therapeutics
- Healthcare median
Show the numbers
| Year | Entrada Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −565.5% | −30.6% |
| FY24 | 31.1% | −47% |
| FY23 | −5.2% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |